Artificial intelligence (AI) is revolutionizing radioligand therapy (RLT) by shifting it from a rigid, high-risk manufacturing process to a predictive, self-optimizing system that coordinates isotope production, radiolabeling, quality control, logistics and individual patient dosing.
The report includes:
- Impact analysis of artificial intelligence (AI) on the global radioligand therapeutics market for cancer treatment
- Case studies for successful integration of AI and machine learning in target identification, radioligand design, dosimetry optimization and clinical trial development
- Highlights of AI adoption trends across major geographical regions, as well as disruptions caused by AI across key oncology, pharmaceutical and biotechnology industry verticals
- AI’s role in precision oncology, therapeutic development, treatment planning and clinical decision-making
- Review of AI impact on the various stages of the global radioligand therapeutics development and supply chain analysis
- Competitive landscape featuring key strategic initiatives, market spendings and an investment outlook
Table of Contents
Chapter 1 Key Use Cases for AI Implementation- Overview
- Key Use Cases
- Use Case 1: Predictive Isotope Yield and Radiolabeling Optimization
- Use Case 2: AI-Driven Hot-Chain Logistics and Dose Scheduling
- Use Case 3: Adaptive Dosimetry and Real-Time Treatment Optimization
- Overview
- Adoption Trends by Region
- Adoption Trends in North America
- Adoption Trends in Europe
- Adoption Trends in Emerging Markets
- Overview
- Impact of AI on Key Industry Verticals
- Biopharma Innovators and Developers
- CDMOs and Radiopharmacy Networks
- Equipment Manufacturers, Isotope Suppliers and Digital Partners
- Hospitals, Nuclear Medicine Centers and Oncologists
- Impact of AI on the Supply Chain
- Plan and Source (Demand Sensing and Isotope Forecasting)
- Make (Real-Time Optimization of Radiolabeling and Compounding)
- Quality and Release (Continuous Verification and Exception-Based Approval)
- Deliver and Improve (Decay-Aware Logistics and Closed-Loop Learning)
- Conclusion
- Overview
- Key Spending in AI in the Radioligand Therapeutics Industry
- Conclusion
- Abbreviations Used in the Report
Table 1: Recent Development in AI in Radioligand Therapeutics Industry, 2022-2025
Table 2: Abbreviations Used in This Report
List of Figures
Figure 1: Impact of AI on the Radioligand Therapeutics Supply Chain
